3 recruiting, 3 withdrawn, 2 completed, 1 not yet recruiting. 5 Not applicable, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Withdrawn 2, Recruiting 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow HepQuant, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Validation of Different Methods for HepQuant DuO® Blood Sample Collection HepQuant DuO Test - Healthy Adult Participants, Liver Disease Chronic | Not yet recruiting | HepQuant, LLC | 200 | 2026-09-18 | 2026-09-17 | |
| Cholate Clearance in Fontan and Heart Failure Dual cholate clearance assay, MRI - Fontan, Right Heart Failure | Recruiting | HepQuant, LLC | 75 | 2025-08-04 | 2026-09-17 | |
| HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer HepQuant DuO, Multiparametric MRI Scans - Liver Cancer, Hepatocellular Carcinoma | Not applicable | Recruiting | Montefiore Medical Center | 40 | 2025-07-16 | 2026-08-11 |
| Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease HepQuant DuO Test - Alcoholic Hepatitis, Alcohol-related Liver Disease | Recruiting | HepQuant, LLC | 40 | 2025-06-10 | 2026-09-16 | |
| A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer Multiparametric MRI scans, Multiparametric MRI scans + HepQuantShunt Test - Cancer, Hepatocellular, Radiotherapy Side Effect | Not applicable | Withdrawn | Montefiore Medical Center | 2025-01-01 | 2025-03-18 | |
| HepQuant to Predict Hepatic Encephalopathy After TIPS HepQuant - Hepatic Encephalopathy, Cirrhosis, Liver | Not applicable | Withdrawn | Northwestern University | 2020-02-25 | 2022-08-09 | |
| The SHUNT-V Study for Varices HepQuant SHUNT Liver Diagnostic Test - Chronic Liver Disease | Not applicable | Completed | HepQuant, LLC | 306 | 2019-01-23 | 2025-04-11 |
| The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology HepQuant SHUNT Liver Diagnostic Kit - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Terminated | HepQuant, LLC | 17 | 2017-12-08 | 2021-08-09 |
| Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 GS-4997, Prednisolone, HepQuant SHUNT Test - Severe Alcoholic Hepatitis | Early Phase 1 | Withdrawn | HepQuant, LLC | 2016-07-31 | 2021-08-30 | |
| Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123) - Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease | Not applicable | Completed | HepQuant, LLC | 48 | 2012-01-01 | 2021-07-15 |
Hepatitis, Alcoholic (2) · Liver Neoplasms (2) · Non-alcoholic Fatty Liver Disease (2) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Fatty Liver (1) · Heart Failure (1) · Hepatic Encephalopathy (1) · Hepatitis (1) · Hepatitis C, Chronic (1) · Liver Cirrhosis (1) · Radiation Injuries (1)
Prednisolone (1)
United States (8)
Greg Everson, MD (3) · James R Burton, MD (1) · Rafi Kabarriti, MD (1) · Rafi Kabbarriti, MD (1)
2023 (1), 2025 (1)